Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial

Paccagnella, Adriano; Favaretto, Adolfo; Oniga, Francesco; Barbieri, Fausto; Ceresoli, Giovanni Luca; Torri, Valter; Villa, Eugenio; Verusio, Claudio; Cetto, Gianluigi; Santo, Antonio; Pangher, V. De; Artioli, Fabrizio; Cacciani, Giancarlo; Parodi, Gonzalo; Soresi, F.; Ghi, Maria Grazia; Morabito, Alessandro; Biason, R.; Giusto, Mauro; Mosconi, Paola; Chiarion-Sileni, Vanna

doi:10.1016/s0169-5002(03)00280-0

Cited by 56 publications

(40 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The scale for hair loss is often used to assess the QoL as related to chemotherapy or radiotherapy for various types of cancer (24,25). The scale for hair loss from the EORTC QLQ-STO22 sheds light on how a history of gastric cancer affects the survivors long after surgery although they were considered to be free of disease.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life of Long-Term Survivors after a Distal Subtotal Gastrectomy

Lee

Chung

2010

Cancer Res Treat

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Quality of Life of Long-Term Survivors after a Distal Subtotal Gastrectomy

Lee

Chung

2010

Cancer Res Treat

View full text Add to dashboard Cite

“…Several trials in the past compared regimens containing cisplatin vs carboplatin with conflicting results [26][27][28][29][30][31][32][33]. In 2007, an individual patient data meta-analysis performed by Ardizzoni et al [34], including 9 of these trials and comparing cisplatin VS carboplatin-based chemotherapy in 2968 NSCLC patients, showed a significant improvement of ORR in favour of cisplatin arm (30% VS 24%; OR: 1.37, P < 0.001), while no significant differences between two arms were observed in survival rate.…”

Section: Citaɵonmentioning

confidence: 99%

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Bronte

Rolfo

Passiglia

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…4,5 Several novel chemotherapeutic agents currently are being evaluated for the treatment of patients with advanced NSCLC. The combination of gemcitabine and carboplatin (GC) is a promising carboplatin-containing regimen and has been evaluated in several randomized trials.…”

mentioning

confidence: 99%

Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer

Yamamoto¹,

Nakagawa²,

Uejima³

et al. 2006

Cancer

View full text Add to dashboard Cite

BACKGROUND. Combined gemcitabine and carboplatin (GC) and combined gemcitabine and vinorelbine (GV) are active and well tolerated chemotherapeutic regimens for patients with advanced nonsmall cell lung cancer (NSCLC). The authors conducted a randomized Phase II study of GC versus GV to compare them in terms of efficacy and toxicity. METHODS. One hundred twenty‐eight patients with Stage IIIB or IV NSCLC were randomized to receive either carboplatin at an area under the curve of 5 on Day 1 combined with gemcitabine 1000 mg/m2 on Days 1 and 8 (n = 64 patients) or vinorelbine 25 mg/m2 combined with gemcitabine 1000 mg/m2 on Days 1 and 8 (n = 64 patients) every 3 weeks. RESULTS. Response rates were 20.3% for the GC patients and 21.0% for the GV patients. In the GC arm, the median survival was 432 days, and the a 1‐year survival rate was 57.6%; in the GV arm, the median survival was 385 days, and the 1‐year survival rate was 53.3% in the GV arm. The median progression‐free survival was 165 days in the GC arm and 137 days in the GV arm. Severe hematologic toxicity (Grade 4) was significantly more frequent in the GC arm (45.3% vs. 25.8% in the GV arm; P = .022). Most notably, the incidence of Grade 3 or 4 thrombocytopenia was significantly higher in the GC arm (81.3% vs. 6.5% in the GV arm; P < .001). Conversely, severe nonhematologic toxicity (Grade 3 or 4) was more common in the GV arm (7.8% vs. 19.4% in the GC arm; P = .057). CONCLUSIONS. Although the GV and GC regimens had different toxicity profiles, there was no significant difference in survival among patients with NSCLC in the current study. Cancer 2006. © 2006 American Cancer Society.

show abstract

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial

Cited by 56 publications

References 19 publications

Quality of Life of Long-Term Survivors after a Distal Subtotal Gastrectomy

Quality of Life of Long-Term Survivors after a Distal Subtotal Gastrectomy

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer

Contact Info

Product

Resources

About